Revised forecast
Fiscal year ending March 2027 · Second quarter (interim period) (1 April 2026 to 30 September 2026)Previous forecast published 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Operating income, ordinary income, and interim net income attributable to owners of the parent are expected to exceed the previously announced forecasts because construction revenue in the Fastener Business that was scheduled to be recognized in the second half is now expected to be recognized in the first half, profits in the Construction Business are expected to exceed the initial assumptions following budget revisions for large-scale construction projects, and selling, general and administrative expenses are expected to be incurred in the second half later than initially assumed.
| Item | Details |
|---|---|
| Net Sales | Consolidated 12,000 / Individual 11,500 → Consolidated 12,000 / Individual 11,500（Consolidated 0 / Individual 0） |
| Operating profit | Consolidated 350 / Individual Not disclosed → Consolidated 860 / Individual Not disclosed（Consolidated 145.7 / Individual Not disclosed） |
| Ordinary income | Consolidated 400 / Individual 370 → Consolidated 960 / Individual 850（Consolidated 140 / Individual 129.7） |
| Profit attributable to owners of the parent | Consolidated (interim net income attributable to owners of the parent) 270 / Non-consolidated (interim net income) 250 → Consolidated (interim net income attributable to owners of the parent) 670 / Non-consolidated (interim net income) 640（Consolidated (interim net income attributable to owners of the parent) 148.1 / Non-consolidated (interim net income) 156） |
| Net income per share | Consolidated (interim net income per share) ¥36.69 / Non-consolidated (interim net income per share) ¥33.97 → Consolidated (interim net income per share) ¥91.04 / Non-consolidated (interim net income per share) ¥86.96 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Second quarter (interim period) (1 April 2026 to 30 September 2026) |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | Consolidated: net sales of ¥12,284 million, operating income of ¥265 million, ordinary income of ¥319 million, interim net income attributable to owners of the parent of ¥215 million, and interim net income per share of ¥29.26. Non-consolidated: net sales of ¥10,827 million, ordinary income of ¥138 million, interim net income of ¥97 million, and interim net income per share of ¥13.25 (second quarter of the fiscal year ended March 2026) |
| Reason for the revision | Operating income, ordinary income, and interim net income attributable to owners of the parent are expected to exceed the previously announced forecasts because construction revenue in the Fastener Business that was scheduled to be recognized in the second half is now expected to be recognized in the first half, profits in the Construction Business are expected to exceed the initial assumptions following budget revisions for large-scale construction projects, and selling, general and administrative expenses are expected to be incurred in the second half later than initially assumed. |
| Consolidated / non-consolidated | Consolidated and non-consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Profit is expected to exceed the initial forecast because construction revenue in the Fastener Business that was scheduled to be recognized in the second half is now expected to be recognized in the first half, profits in the Construction Business are expected to exceed the initial assumptions following budget revisions for large-scale construction projects, and selling, general and administrative expenses are expected to be incurred in the second half later than initially assumed.